Understand the source comparison
Epithalon Safety vs Other Longevity Interventions
Epithalon (5–10mg, 10-day cycles) 1.2% (mild, self-limiting) Theoretical telomerase cancer risk (unobserved clinically) 15-year longitudinal data (266 participants) Well-tolerated with extensive safety record; theoretical risks remain unmanifested Metformin (o
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Epithalon (5–10mg, 10-day cycles)
- 1.2% (mild, self-limiting)
- Theoretical telomerase cancer risk (unobserved clinically)
- 15-year longitudinal data (266 participants)
- Well-tolerated with extensive safety record; theoretical risks remain unmanifested
- Metformin (off-label longevity)
- 25–30% GI side effects
- Lactic acidosis (rare but serious), vitamin B12 depletion, GI disturbance
- 60+ years clinical use (primarily diabetes indication)
- Proven safety in disease context; longevity application extrapolated from disease data
- Rapamycin (off-label longevity)
- 15–20% metabolic disruption
- Immunosuppression, glucose dysregulation, hyperlipidemia
- 25+ years transplant data; 5 years longevity research
- Serious immunosuppressive effects limit long-term use outside controlled research
- NAD+ precursors (NMN, NR)
- 5–10% flushing, GI upset
- Methylation pathway disruption, unclear long-term metabolic effects
- 3–5 years human data
- Generally safe short-term; long-term metabolic impacts inadequately studied
- Growth hormone peptides (MK 677)
- 20–30% water retention, appetite
- Insulin resistance risk, IGF-1 elevation concerns
- 10+ years (growth hormone deficiency context)
- Effective but requires metabolic monitoring; not appropriate for unsupervised use
- The comparison underscores a critical point: Epithalon's safety profile compares favourably to pharmaceutical interventions with decades of clinical use. Metformin. Considered one of the safest longevity candidates. Produces gastrointestinal side effects in 25–30% of users and carries a black-box warning for lactic acidosis. Rapamycin's immunosuppressive effects preclude continuous use outside transplant contexts. Epithalon's 1.2% adverse event rate, with zero serious events, positions it as one of the most well-tolerated compounds in longevity research.